Coulter Partners recruits Chief Medical Officer for Albumedix


Coulter Partners was delighted to partner with Albumedix to secure the appointment of Dr. Giles Campion as Chief Medical Officer.

Albumedix develops albumin-enabled therapeutics using its albumin-based products and technologies for advanced drug and vaccine formulation, extended drug half-life and improved drug delivery. Using its products and technologies, Albumedix is advancing a pipeline of proprietary and partnered drug programs in clinic and the market together with pharmaceutical companies worldwide. Albumedix is a global, science-driven biotech company and a fully owned subsidiary of Novozymes A/S. Dr. Campion brings with him more than 25 years’ experience in drug development from both large pharma and biotech companies having worked in senior development positions in the US as well as Europe.

The appointment is key to the company’s on-going strategy of strengthening its albumin-based drug delivery platform to support the development of improved bio-therapeutics. Dr. Campion will be responsible for building Albumedix’s pipeline and leading global development efforts based on its albumin technology which presents great opportunities for creating biopharmaceuticals with optimized therapeutic profiles. He will join Albumedix’s Executive Management team, reporting to the company’s Chief Executive Officer, Peter Rosholm, who comments:

“I am delighted to welcome Giles Campion to Albumedix and I thank the exceptional team at Coulter Partners for conducting such a successful search on our behalf. Giles’ depth of experience across multiple therapeutic indications, drug development track record and expertise in the filings of specialized pharmaceuticals, will be invaluable to us as we move our pre-clinical drug candidates towards the clinic. This appointment marks the latest step in our growth strategy as we work to advance breakthroughs in the use of albumin in the development of life-changing therapeutics.”

Prior to joining Albumedix, Dr. Campion was SVP Research and Development and CMO at Prosensa Holdings and then Group Vice President, Neuromuscular Franchise at Biomarin following the Prosensa acquisition. Previously he has held positions such as Global Head of Clinical Research and Development at General Electric Healthcare and European Head of Exploratory Clinical Development at Novartis. With experience across all therapeutic areas, most recently in orphan neuromuscular disorders, Dr. Campion has overseen global and regional filing and approvals of new products in cardiovascular disease diabetes, oncology, neurodegenerative disease and hormone deficiency. During his career he has overseen the development of over 40 therapeutics and diagnostic agents.

“Albumedix is redefining the use of albumin-based drug enhancing technologies and I’m delighted to join the company at this exciting time in its development,” said Dr. Campion. “The company’s technologies and in-depth albumin expertise are providing many new pipeline opportunities, and I look forward to contributing to its future growth.”